共 133 条
[1]
Lee S(2012)Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States J Med Econ 15 1088-1096
[2]
Baxter DC(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
[3]
Limone B(2011)Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 1293-1303
[4]
Cohen JA(2012)Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 1098-1107
[5]
Barkhof F(2004)Evaluation and review of pharmacoeconomic models Expert Opin Pharmacother 5 1867-1880
[6]
Comi G(2010)The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability Brain 133 1914-1929
[7]
O’Connor P(2008)What does the value of modern medicine say about the $50,000 per quality-adjusted life year decision rule? Med Care 46 349-356
[8]
Wolinsky JS(2013)Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States PharmacoEconomics 31 823-839
[9]
Confavreux C(2014)Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer Gynecol Oncol 132 677-683
[10]
Gold R(2013)The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States: a literature review and Markov Model Neuro Oncol 15 1532-1542